Category: 3. Business

  • Assessing Panasonic (TSE:6752) Valuation After Recent Share Price Cool-Down and Strong Long-Term Returns

    Assessing Panasonic (TSE:6752) Valuation After Recent Share Price Cool-Down and Strong Long-Term Returns

    Panasonic Holdings (TSE:6752) has captured attention as investors digest recent numbers and look at what the stock’s performance tells us about the company’s direction. The discussion focuses on its underlying fundamentals and how shares have moved over the past year.

    See our latest analysis for Panasonic Holdings.

    Panasonic Holdings’ share price has cooled off a bit over the past month, dipping 4.4%, but that comes after a strong run with a 12.5% gain in the previous quarter. All told, the company’s one-year total shareholder return sits at a solid 15%. The three- and five-year figures, 46% and 75% respectively, suggest that long-term momentum remains firmly intact, reflecting optimism about its growth prospects.

    If you’re curious about what else is building momentum in the sector, now’s a great time to explore the auto manufacturers landscape with See the full list for free.

    But with shares trading at a meaningful discount to analyst targets and robust earnings growth behind it, the key question is whether Panasonic Holdings is undervalued right now or if the market is already factoring in future gains.

    Compared to Panasonic Holdings’ last close price, the most followed narrative assigns a much higher fair value, suggesting the market may be discounting future growth potential. This framework brings together analyst price targets, earnings power, and margin forecasts to set its target.

    Demand for industrial energy storage systems is accelerating beyond initial expectations due to large-scale data center investment driven by generative AI adoption. This is likely to support revenue growth and improve recurring earnings quality in the Energy segment. Despite a near-term EV slowdown in North America from policy headwinds (IRA tax credit termination, tariffs), Panasonic’s locally produced, IRA-compliant battery cells and new high-capacity cell technology are sustaining strong customer demand. This positions the company for volume growth and higher net margins as electrification resumes its long-term trend.

    Read the complete narrative.

    What is behind this bullish price view? The narrative is built on aggressive projections for profit expansion and margin improvement, along with critical long-term bets on new battery technologies. Want to discover exactly how analysts justify this higher valuation and which future milestones could make or break it?

    Result: Fair Value of ¥2,126.67 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, risks such as a slowdown in EV demand or increased tariffs could quickly shift Panasonic Holdings’ outlook away from the current bullish narrative.

    Find out about the key risks to this Panasonic Holdings narrative.

    If this perspective doesn’t quite fit your view, or if you enjoy digging into the numbers yourself, it’s easy to craft your own take in just a few minutes. Do it your way

    A great starting point for your Panasonic Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

    Missing out on these fresh stock ideas could cost you the opportunity to catch tomorrow’s leaders early. Supercharge your research with these handpicked investment angles below.

    • Tap into long-term income by scanning these 16 dividend stocks with yields > 3% offering impressive yields above 3% and a solid track record of shareholder rewards.

    • Ride the AI momentum by reviewing these 26 AI penny stocks building intelligent solutions for tomorrow’s world and securing footholds in high-growth sectors.

    • Benefit from sector innovation and resilience with these 30 healthcare AI stocks tackling the toughest challenges in medical technology and healthcare advancement.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include 6752.T.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Multienzymatic nanocatalysts attenuate acute pancreatitis via dual modulation of pyroptotic pathways and autodigestion blockade | Journal of Nanobiotechnology

    Multienzymatic nanocatalysts attenuate acute pancreatitis via dual modulation of pyroptotic pathways and autodigestion blockade | Journal of Nanobiotechnology

  • Iannuzzi JP, King JA, Leong JH, Quan J, Windsor JW, Tanyingoh D, et al. Global incidence of acute pancreatitis is increasing over time: A systematic review and meta-analysis. Gastroenterology. 2022;162(1):122–34.

    Google Scholar 

  • Mederos MA, Reber HA, Girgis MD. Acute pancreatitis: a review. JAMA. 2021;325(4):382–90.

    Google Scholar 

  • Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, et al. Acute pancreatitis: Diagnosis and treatment. Drugs. 2022;82(12):1251–76.

    Google Scholar 

  • Boxhoorn L, Voermans RP, Bouwense SA, Bruno MJ, Verdonk RC, Boermeester MA, et al. Acute pancreatitis. Lancet. 2020;396(10252):726–34.

    Google Scholar 

  • Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol. 2019;16(8):479–96.

    Google Scholar 

  • IAP/APA evidence-based guidelines for the management of acute pancreatitis, Pancreatology official journal of the International Association of Pancreatology (IAP) et al. 2013;13:e1 15.

  • Hackert T, Werner J. Antioxidant therapy in acute pancreatitis: experimental and clinical evidence. Antioxid Redox Signal. 2011;15(10):2767–77.

    Google Scholar 

  • Liu L, Zhang Y, Li X, Deng J. Microenvironment of pancreatic inflammation: Calling for nanotechnology for diagnosis and treatment. J Nanobiotechnol. 2023;21(1):443.

    Google Scholar 

  • Sah RP, Garg P, Saluja AK. Pathogenic mechanisms of acute pancreatitis. Curr Opin Gastroenterol. 2012;28(5):507–15.

    Google Scholar 

  • Jakkampudi A, Jangala R, Reddy BR, Mitnala S, Reddy DN, Talukdar R, et al. NF-κb in acute pancreatitis: Mechanisms and therapeutic potential. Pancreatology. 2016;16(4):477–88.

    Google Scholar 

  • Vasudevan SO, Behl B, Rathinam VA. Pyroptosis-induced inflammation and tissue damage. Semin Immunol. 2023;69:101781.

    Google Scholar 

  • Du G, Healy LB, David L, Walker C, El-Baba TJ, Lutomski CA, et al. ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D. Nature. 2024;630(8016):437–46.

    Google Scholar 

  • Ren F, Xu J, Zhang J, Xu X, Huang L, Sun W, et al. PM(2.5) induced lung injury through upregulating ROS-dependent NLRP3 inflammasome-mediated pyroptosis. Immunobiology. 2022;227(3):152207.

    Google Scholar 

  • Zhang Y, Fang C, Zhang W, Zhang K. Emerging pyroptosis-engineered nanobiotechnologies regulate cancers and inflammatory diseases: A double-edged sword. Matter. 2022;5(11):3740–74.

    Google Scholar 

  • Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245–54.

    Google Scholar 

  • Zhou J, Fang C, Rong C, Luo T, Liu J, Zhang K. Reactive oxygen species-sensitive materials: A promising strategy for regulating inflammation and favoring tissue regeneration. Smart Mater Med. 2023;4:427–46.

    Google Scholar 

  • Zhang R, Yan X, Fan K. Nanozymes inspired by natural enzymes. Acc Mater Res. 2021;2(7):534–47.

    Google Scholar 

  • Gao L, Wei H, Dong S, Yan X. Nanozymes. Adv Mater. 2024;36(10):e2305249.

    Google Scholar 

  • Liang M, Yan X. Nanozymes: from new concepts, mechanisms, and standards to applications. Acc Chem Res. 2019;52(8):2190–200.

    Google Scholar 

  • Hai X, Xi S, Mitchell S, Harrath K, Xu H, Akl DF, et al. Scalable two-step annealing method for preparing ultra-high-density single-atom catalyst libraries. Nat Nanotechnol. 2022;17(2):174–81.

    Google Scholar 

  • Chen Y, Wang P, Hao H, Hong J, Li H, Ji S, et al. Thermal atomization of platinum nanoparticles into single atoms: An effective strategy for engineering high-performance nanozymes. J Am Chem Soc. 2021;143(44):18643–51.

    Google Scholar 

  • Hua S, Dong X, Peng Q, Zhang K, Zhang X, Yang J. Single-atom nanozymes shines diagnostics of gastrointestinal diseases. J Nanobiotechnol. 2024;22(1):286.

    Google Scholar 

  • Zhang R, Yan X, Gao L, Fan K. Nanozymes expanding the boundaries of biocatalysis. Nat Commun. 2025;16(1):6817.

    Google Scholar 

  • Li Q, Zeng M, Pu XY, Tang Q, Yang Q, Zhang LK. Melittin-Loaded Multifunctional Nanozyme for Ulcerative Colitis Treatment via Enzyme-Immunotherapy and Ferroptosis Inhibition, Advanced functional materials. 2025.

  • Cao F, Jin L, Gao Y, Ding Y, Wen H, Qian Z, et al. Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis. Nat Nanotechnol. 2023;18(6):617–27.

    Google Scholar 

  • Chen J, Zhao Y, Ruan R, Feng X, Niu Z, Pan L, et al. Bone morphogenetic protein-2-derived peptide-conjugated nanozyme-integrated photoenhanced hybrid hydrogel for cascade-regulated bone regeneration. ACS Nano. 2025;19(15):14707–26.

    Google Scholar 

  • Li D, Ai Z, Tian Y, Wang Y, Zhang C. Bioactive prosthetic interface constructed with cascading multi-nanozyme hydrogel to induce M2 macrophage polarization and heal diabetic bone defects. Biomaterials. 2025;325:123624.

    Google Scholar 

  • Li H, Wei S, Ling Q, Wang R, Liu T, Yu H, et al. Nanozyme-reinforced hydrogel spray as a reactive oxygen species-driven oxygenator to accelerate diabetic wound healing. Adv mater (Deerfield Beach, Fla). 2025;37(34):e2504829.

    Google Scholar 

  • Xuan Q, Cai J, Gao Y, Qiao X, Jin T, Peydayesh M, et al. Amyloid-templated ceria nanozyme reinforced microneedle for diabetic wound treatments. Adv mater (Deerfield Beach, Fla). 2025;37(15):e2417774.

    Google Scholar 

  • Shan Y, Zhong J, Sun Q, Gao W, Zhang C, Chen H, et al. Dual nanozymes-loaded core-shell microneedle patches with antibacterial and NETs-degradation bifunctional properties for periodontitis treatment. Bioact Mater. 2025;53:161–77.

    Google Scholar 

  • Wang D, Jin H, Shen Y, Wang D, He J, Qu J, et al. NIR-II-activated iridium single-atom nanozymes for synergistic antibacterial therapy and tissue regeneration in MRSA-infected wounds and acute lung injury. Bioact Mater. 2025;51:543–58.

    Google Scholar 

  • Lee H, Krishnan M, Kim M, Yoon YK, Kim Y. Rhamnetin, a natural flavonoid, ameliorates organ damage in a mouse model of carbapenem-resistant acinetobacter baumannii-induced sepsis. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms232112895.

    Google Scholar 

  • Novo Belchor M, Hessel Gaeta H, FabriBittencourt Rodrigues C, Ramos C, da Cruz Costa D, de Oliveira Toyama LF, et al. Evaluation of Rhamnetin as an inhibitor of the pharmacological effect of secretory phospholipase A2. Mol (Basel, Switz). 2017;22(9):1420–3049.

    Google Scholar 

  • Park ES, Kang JC, Jang YC, Park JS, Jang SY, Kim DE, et al. Cardioprotective effects of rhamnetin in H9c2 cardiomyoblast cells under H₂O₂-induced apoptosis. J Ethnopharmacol. 2014;153(3):552–60.

    Google Scholar 

  • Bull SD, Davidson MG, van den Elsen JM, Fossey JS, Jenkins AT, Jiang YB, et al. Exploiting the reversible covalent bonding of boronic acids: Recognition, sensing, and assembly. Acc Chem Res. 2013;46(2):312–26.

    Google Scholar 

  • Geng W, Jiang N, Qing GY, Liu X, Wang L, Busscher HJ, et al. Click reaction for reversible encapsulation of single yeast cells. ACS Nano. 2019;13(12):14459–67.

    Google Scholar 

  • Zhang K, Cheng Y, Ren W, Sun L, Liu C, Wang D, et al. Coordination-responsive longitudinal relaxation tuning as a versatile MRI sensing protocol for malignancy targets. Adv Sci. 2018;5(9):1800021.

    Google Scholar 

  • Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: Mechanisms and diseases. Signal Transduct Target Ther. 2021;6(1):128.

    Google Scholar 

Continue Reading

  • Low-Cost, High-Impact Teaching in Pharmacology: A Mixed-Methods Study Assessing the Effectiveness of a Ball-and-Balloon Activity on Student Engagement and Learning Outcomes

    Low-Cost, High-Impact Teaching in Pharmacology: A Mixed-Methods Study Assessing the Effectiveness of a Ball-and-Balloon Activity on Student Engagement and Learning Outcomes

    Continue Reading

  • Audit of Shoulder Dystocia Management and Outcomes at a Busy Hospital in the United Kingdom: A Comprehensive Analysis of Contemporary Practice

    Audit of Shoulder Dystocia Management and Outcomes at a Busy Hospital in the United Kingdom: A Comprehensive Analysis of Contemporary Practice

    Continue Reading

  • Effects of seven types of exercise in the treatment of rotator cuff-related shoulder pain (RCRSP): a systematic review and Bayesian network meta-analysis | Journal of Orthopaedic Surgery and Research

    Effects of seven types of exercise in the treatment of rotator cuff-related shoulder pain (RCRSP): a systematic review and Bayesian network meta-analysis | Journal of Orthopaedic Surgery and Research

  • Bedi A, Bishop J, Keener J, et al. Rotator cuff tears. Nat Rev Dis Primers. 2024;10(1):8.

    Google Scholar 

  • Lewis J. Rotator cuff related shoulder pain: assessment, management and uncertainties. Man Ther. 2016;23:57–68.

    Google Scholar 

  • Lewis J, McCreesh K, Roy JS, Ginn K. Rotator cuff tendinopathy: navigating the diagnosis-management conundrum. J Orthop Sports Phys Ther. 2015;45(11):923–37.

    Google Scholar 

  • Vandvik PO, Lähdeoja T, Ardern C, et al. Subacromial decompression surgery for adults with shoulder pain: a clinical practice guideline. BMJ. 2019;364:l294.

    Google Scholar 

  • Lafrance S, Ouellet P, Alaoui R, et al. Motor control exercises compared to strengthening exercises for upper- and lower-extremity musculoskeletal disorders: a systematic review with meta-analyses of randomized controlled trials. Phys Ther. 2021;101(7):11.

    Google Scholar 

  • Littlewood C, Ashton J, Chance-Larsen K, May S, Sturrock B. Exercise for rotator cuff tendinopathy: a systematic review. Physiotherapy. 2012;98(2):101–9.

    Google Scholar 

  • Lafrance S, Charron M, Dubé OM, et al. The efficacy of exercise therapy for rotator cuff-related shoulder pain according to the FITT principle: a systematic review with meta-analyses. J Orthop Sports Phys Ther. 2024;54(8):499–512.

    Google Scholar 

  • Scott A, Squier K, Alfredson H, et al. ICON 2019: international scientific tendinopathy symposium consensus: clinical terminology. Br J Sports Med. 2020;54(5):260–2.

    Google Scholar 

  • McQuade KJ, Borstad J, de Oliveira AS. Critical and theoretical perspective on scapular stabilization: what does it really mean, and are we on the right track? Phys Ther. 2016;96(8):1162–9.

    Google Scholar 

  • Rees JD, Wolman RL, Wilson A. Eccentric exercises; why do they work, what are the problems and how can we improve them? Br J Sports Med. 2009;43(4):242–6.

    Google Scholar 

  • Malliaras P, Johnston R, Street G, et al. The efficacy of higher versus lower dose exercise in rotator cuff tendinopathy: a systematic review of randomized controlled trials. Arch Phys Med Rehabil. 2020;101(10):1822–34.

    Google Scholar 

  • Baskurt Z, Baskurt F, Gelecek N, Ozkan MH. The effectiveness of scapular stabilization exercise in the patients with subacromial impingement syndrome. J Back Musculoskelet Rehabil. 2011;24(3):173–9.

    Google Scholar 

  • Berg OK, Paulsberg F, Brabant C, et al. High-intensity shoulder abduction exercise in subacromial pain syndrome. Med Sci Sports Exerc. 2021;53(1):1–9.

    Google Scholar 

  • Blume C, Wang-Price S, Trudelle-Jackson E, Ortiz A. Comparison of eccentric and concentric exercise interventions in adults with subacromial impingement syndrome. Int J Sports Phys Ther. 2015;10(4):441–55.

    Google Scholar 

  • Boudreau N, Gaudreault N, Roy JS, Bédard S, Balg F. The addition of glenohumeral adductor coactivation to a rotator cuff exercise program for rotator cuff tendinopathy: a single-blind randomized controlled trial. J Orthop Sports Phys Ther. 2019;49(3):126–35.

    Google Scholar 

  • Clausen MB, Hölmich P, Rathleff M, et al. Effectiveness of adding a large dose of shoulder strengthening to current nonoperative care for subacromial impingement: a pragmatic, double-blind randomized controlled trial (SExSI trial). Am J Sports Med. 2021;49(11):3040–9.

    Google Scholar 

  • Dejaco B, Habets B, van Loon C, van Grinsven S, van Cingel R. Eccentric versus conventional exercise therapy in patients with rotator cuff tendinopathy: a randomized, single blinded, clinical trial. Knee Surg Sports Traumatol Arthrosc. 2017;25(7):2051–9.

    Google Scholar 

  • Dubé MO, Desmeules F, Lewis JS, Roy JS. Does the addition of motor control or strengthening exercises to education result in better outcomes for rotator cuff-related shoulder pain? A multiarm randomised controlled trial. Br J Sports Med. 2023;57(8):457–63.

    Google Scholar 

  • Heron SR, Woby SR, Thompson DP. Comparison of three types of exercise in the treatment of rotator cuff tendinopathy/shoulder impingement syndrome: a randomized controlled trial. Physiotherapy. 2017;103(2):167–73.

    Google Scholar 

  • Hotta GH, De Assis G, Couto A, Cools AM, McQuade KJ, Siriani De Oliveira A. Effects of adding scapular stabilization exercises to a periscapular strengthening exercise program in patients with subacromial pain syndrome: a randomized controlled trial. Musculoskelet Sci Pract. 2020;49:102171.

    Google Scholar 

  • Ingwersen KG, Jensen SL, Sørensen L, et al. Three months of progressive high-load versus traditional low-load strength training among patients with rotator cuff tendinopathy: primary results from the double-blind randomized controlled RoCTEx trial. Orthop J Sports Med. 2017;5(8):2325967117723292.

    Google Scholar 

  • Kamonseki DH, Haik MN, Ribeiro LP, Almeida RF, Camargo PR. Scapular movement training is not superior to standardized exercises in the treatment of individuals with chronic shoulder pain and scapular dyskinesis: randomized controlled trial. Disabil Rehabil. 2023;45(18):2925–35.

    Google Scholar 

  • Macías-Hernández SI, García-Morales JR, Hernández-Díaz C, Tapia-Ferrusco I, Velez-Gutiérrez OB, Nava-Bringas TI. Tolerance and effectiveness of eccentric vs. concentric muscle strengthening in rotator cuff partial tears and moderate to severe shoulder pain. A randomized pilot study. J Clin Orthop Trauma. 2021;14:106–12.

    Google Scholar 

  • Maenhout AG, Mahieu NN, De Muynck M, De Wilde LF, Cools AM. Does adding heavy load eccentric training to rehabilitation of patients with unilateral subacromial impingement result in better outcome? A randomized, clinical trial. Knee Surg Sports Traumatol Arthrosc. 2013;21(5):1158–67.

    Google Scholar 

  • Marzetti E, Rabini A, Piccinini G, et al. Neurocognitive therapeutic exercise improves pain and function in patients with shoulder impingement syndrome: a single-blind randomized controlled clinical trial. Eur J Phys Rehabil Med. 2014;50(3):255–64.

    Google Scholar 

  • Struyf F, Nijs J, Mollekens S, et al. Scapular-focused treatment in patients with shoulder impingement syndrome: a randomized clinical trial. Clin Rheumatol. 2013;32(1):73–85.

    Google Scholar 

  • Chaconas EJ, Kolber MJ, Hanney WJ, Daugherty ML, Wilson SH, Sheets C. Shoulder external rotator eccentric training versus general shoulder exercise for subacromial pain syndrome: a randomized controlled trial. Int J Sports Phys Ther. 2017;12(7):1121–33.

    Google Scholar 

  • Shire AR, Stæhr TAB, Overby JB, Bastholm Dahl M, Sandell Jacobsen J, Høyrup Christiansen D. Specific or general exercise strategy for subacromial impingement syndrome-does it matter? A systematic literature review and meta analysis. BMC Musculoskelet Disord. 2017;18(1):158.

    Google Scholar 

  • Larsson R, Bernhardsson S, Nordeman L. Effects of eccentric exercise in patients with subacromial impingement syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2019;20(1):446.

    Google Scholar 

  • Powell JK, Lewis J, Schram B, Hing W. Is exercise therapy the right treatment for rotator cuff-related shoulder pain? Uncertainties, theory, and practice. Musculoskelet Care. 2024;22(2):e1879.

    Google Scholar 

  • Powell JK, Schram B, Lewis J, Hing W. You have (rotator cuff related) shoulder pain, and to treat it, l recommend exercise. A scoping review of the possible mechanisms underpinning exercise therapy. Musculoskelet Sci Pract. 2022;62:102646.

    Google Scholar 

  • Vila-Dieguez O, Heindel MD, Awokuse D, Kulig K, Michener LA. Exercise for rotator cuff tendinopathy: proposed mechanisms of recovery. Shoulder Elbow. 2023;15(3):233–49.

    Google Scholar 

  • Migliorini F, Maffulli N, Eschweiler J, Schenker H, Tingart M, Betsch M. Arthroscopic versus mini-open rotator cuff repair: a meta-analysis. Surgeon. 2023;21(1):E1–12.

    Google Scholar 

  • Maffulli N, Helander KN, Migliorini F. Tendon appearance at imaging may be altered, but it may not indicate pathology. Knee Surg Sports Traumatol Arthrosc. 2023;31(5):1625–8.

    Google Scholar 

  • Osti L, Del Buono A, Maffulli N. Rotator cuff repair: imaging success and clinical results may not correspond. Orthopedics. 2014;37(1):17–8.

    Google Scholar 

    • Continue Reading

  • How to invest £500 in 2025 like billionaire Warren Buffett

    How to invest £500 in 2025 like billionaire Warren Buffett

    Image source: The Motley Fool

    Anyone new to investing can learn a lot from the sound advice of Warren Buffett. The 95-year-old billionaire is considered the world’s greatest investor, transforming his firm, Berkshire Hathaway, into a $1.1trn super-giant, despite only starting with just $105,100 in 1956.

    Having a hundred grand to kick-start an investing journey is undoubtedly advantageous. Yet, Buffett’s strategy and tactics are still applicable for even the tiniest of investors starting with just £500 today.

    So how can new investors take this small lump sum and transform it into something far more substantial?

    There are two key lessons from Buffett that every novice investor needs to know, in my opinion:

    1. “Rule #1 is never lose money. Rule #2 is never forget Rule # 1”.

    2. “Evaluate companies within your circle of competence”.

    Not every investment Buffett has made has been a success. In fact, there have been some painful mistakes over the years. But by being informed, having some healthy scepticism, and avoiding speculative or reckless investments, the risk of making painful errors can be drastically reduced. That’s how Buffett applies his ‘Rule #1’.

    The second bit of advice is equally as important. Investors don’t need to buy shares in complex bleeding-edge sectors like biotech or exploration-stage mining to make money. Instead, Buffett’s always stuck to the industries that are easy to understand. And some of his most successful investments, like Coca-Cola, have come from these simple sectors.

    In other words, by investing exclusively in industries and companies that are easy to understand, investors can drastically reduce risk from ignorance.

    With all that said, what are some shares that new investors can consider for potentially solid long-term returns?

    There are never any guarantees with any investment since even the most promising of enterprises have to navigate unique risks and challenges. Having said that, one UK Buffett-style stock that I’ve got my eye on right now is Premier Foods (LSE:PFD).

    Premier’s business model is as straightforward as they come. It buys raw ingredients, manufactures food products, and then leverages its branding power to sell them at a premium. And today, 89% of British households buy at least one of its products each year, with an estimated 70% repeat customers.

    In other words, the firm’s brands often find themselves on families’ weekly shopping lists. And with international expansion efforts underway in Australia, Europe, and North America, management‘s seeking to replicate its UK success abroad.

    Is this a high-growth enterprise? No. Is it a highly cash-generative business leveraging its competitive advantages to steadily compound its bottom line? Yes. And with management shoring up the balance sheet over the last five years, the stock’s already more than doubled the performance of the FTSE 100 since 2020.

    Premier Foods still has to deal with the threat of inflationary input costs. While having strong brands certainly helps in passing these costs to customers, weak economic conditions still present a challenge, resulting in both growth and margin pressure.

    Nevertheless, with a proven competitive moat, a discounted valuation, and a long-lasting business model, Premier strikes me as a classic Buffett-style stock to consider. And it’s not the only one, I’ve got my eye on right now.

    The post How to invest £500 in 2025 like billionaire Warren Buffett appeared first on The Motley Fool UK.

    More reading

    Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Premier Foods Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

    Motley Fool UK 2025

    Continue Reading

  • This famous perfume entrepreneur’s only regret is selling her name

    This famous perfume entrepreneur’s only regret is selling her name

    Ms Jo Malone CBE, British perfumer and founder of fragrance brands Jo Malone London and Jo Loves.

    Mike Green, CNBC

    Ms Jo Malone CBE became a millionaire after selling her namesake perfume brand in 1999, and decades later has only one regret: never being able to use her name again.

    Malone founded fragrance brand Jo Malone London in 1990 and sold it to the Estée Lauder Companies nine years later — along with the rights to use her name in any business.

    “I don’t look back and think to myself: ‘If I’d waited another five years, I could have made double the amount,’” the 62-year-old British entrepreneur said on an episode of CNBC’s “Executive Decisions” podcast with Steve Sedgwick.

    But she added: “I think the one thing I regret — and they [Estée Lauder] may not have bought the company [without it] — is the use of my name. That’s a struggle, even today.”

    ‘I feel the law needs to change, actually’

    Under British law, when you sell a business built on your name, you usually sell the goodwill and the right to use that name, Simon Barker, partner and intellectual property head at Freeths law firm, told CNBC Make It.

    Once you’ve sold the business, using your name for a similar business could cause consumer confusion and breach your contract or infringe any trademarks the buyer now owns.

    It could also amount to “passing off” — a British legal concept that stops someone from misleading the public into thinking their goods or services are connected to another business.

    Malone’s later businesses only use her first name to ensure they don’t violate her agreement with Estée Lauder. These include her luxury fragrance brand Jo Loves and, more recently, her alcohol brand Jo Vodka.

    While the sale of her first brand made her wealthy, Malone said sacrificing her name was “the hardest thing.”

    “I don’t want to cause any problems, but I feel the law needs to change, actually, in this, because people are selling their businesses with their names, and if you’re saying you can’t use your name for the rest of your life, that’s a lifelong non-compete,” she said.

    “I think the law is going to have to look at the way businesses are sold and how that non-compete comes in,” she added.

    ‘Contractual restrictions trump everything’

    Malone is one of a number of British entrepreneurs who have sold an eponymous brand only to regret it later.

    Fashion designer Karen Millen sold her business in 2004, and agreed not to use her name in a competing business globally. She later challenged the restrictions, but a court ruled that using her name would cause consumer confusion.

    Meanwhile, Elizabeth Emanuel, the designer behind Princess Diana’s wedding dress, sold her business — including the rights to use her name — to a company that later transferred those rights to new owners. When she tried to stop them from using “Elizabeth Emanuel,” the courts ruled that the sale meant the new owners legally controlled the name and trademark.

    “Contractual restrictions trump everything,” lawyer Barker said. “They go on the top of everything. So if you say: I won’t use my name for a competing business, then the new buyer can enforce that covenant against you.”

    It’s a similar story across the Atlantic. American makeup artist and entrepreneur Bobbi Brown also sold her namesake cosmetics company to Estée Lauder in 1995 and was contractually obliged not to use her name commercially in a way that would compete with the brand.

    While the U.S. has similar laws preventing entrepreneurs from breaking contractual obligations, it also has the “right of publicity,” which is a law that the U.K. doesn’t have.

    This “protects against the unauthorized commercial use of somebody’s name, image or likeness,” Barker explained. “Where the difference lies is that you’ll almost certainly lose the right to use your name for similar goods or services because of the contractual restrictions, but the right of publicity might still allow you to control other uses of your name and advertising or endorsements.”

    Negotiate your contract

    Malone advised young entrepreneurs and first-time founders to think twice before selling the rights to their name.

    “I would say to people, anyone that is looking at acquisition, especially if your name is attached to your business, think through all the implications first,” Malone said. “Think about those things, because you will sacrifice things, and you will have to give and yield, and you will gain something else, but never do it solely, just for money.”

    Barker adds to this that you can negotiate what’s in the contract before selling the business, including perhaps changing the name. However, there are some caveats, as oftentimes, without the original name, the brand doesn’t retain as much value in acquisitions.

    He said founders should consult advisors and potentially ask for “watered-down restrictions.”

    “But of course, it’s not always as simple as that, because somebody will be waving many millions of pounds at you,” he added. “And if you say: ‘I want all of this,’ they’re likely to turn around and say: ‘Well, we’re not going to give you as much then.’”

    Continue Reading

  • Fire alert: the fake ‘Amazon TV stick’ that opens the door to fraudsters | Scams

    Fire alert: the fake ‘Amazon TV stick’ that opens the door to fraudsters | Scams

    The big fight is on TV on Saturday night but you really don’t want to shell out to watch it on pay-per-view. Luckily, you bought a cheap Amazon Fire Stick online that gives you access to all the sports you want as well as TV streaming services.

    While the quality of the picture is not brilliant, you are saving on monthly subscriptions and the one-off fees to watch big sporting events. The stick was a bargain – or so you think.

    In fact, using a “modded” Amazon Fire Stick in your laptop or TV can give criminals an open door to your bank details and passwords, putting you at risk of losing thousands and having your identity traded over the web.

    A recent survey from BeStreamWise, a UK initiative established to counter the problem, found two out of every five people who used illegal streaming were defrauded. They lost an average of almost £1,700 each as a result.

    “Illegal streaming might look like a quick way to save money, but … it’s a false economy that can end up costing people thousands,” says DCI Emma Warbey of the police intellectual property crime unit (PIPCU) at City of London police.

    “This is a crime that diverts funds away from the entertainment industries – money that supports thousands of technical and support staff. At the same time, it exposes end-users to the risks of data theft, cybercrime and fraud.”

    The modded or “jailbroken” devices are Amazon Fire Sticks with extra software added that can be bought for about £20 on the internet.

    The growing use of them has led to a crackdown by the Federation Against Property Theft (Fact), which has been carrying out raids across the UK to stop supply.

    The genuine article: a legitimate ad for the Amazon Fire TV Stick. Photograph: PR Image

    In one case, according to BeStreamWise, a man who was streaming illegally had his bank details stolen twice and someone tried to buy a boat in his name.

    What the scam looks like

    The sticks are sold through social media and illegal streaming sites, often advertised as being jailbroken with promises of free TV shows, sports and films.

    The potential for fraud happens the minute you put the “dodgy stick” into a laptop or TV, according to Rob Shapland of Cyonic Cyber, an ethical hacker who shows companies where there are gaps in their security systems.

    “Alongside the stream [of TV or sports] it will also install some malware on to your computer and give the criminal direct access to your computer so [they] could use it as if they were sitting there,” he says.

    “Or they can install keyloggers which will record any password you are typing. So when you are accessing online banking, it will record your banking passwords. You are essentially volunteering to have your laptop hacked in many cases.”

    Often the stick will come with instructions which appear to be how to install the software but are actually ways to bypass virus detectors.

    When you plug the device into a TV, it can access other devices, such as laptops, through the home wifi network that they are all attached to, says Shapland.

    “It might ask you to log in with your Google account and then you are giving your credentials to the app and that is then sent off to the criminals. Most people tend to reuse the same password so once they have one password, they have access to a hundred different things.”

    Some sticks may ask for a small monthly subscription. Setting up the payment means criminals can use your credit card details in any way they want.

    What to do

    Once you know that the device you are using is illegal, you should remove it from your devices immediately.

    Buying a ‘modded’ USB stick online means you are ‘essentially volunteering to have your laptop hacked in many cases’, says ethical hacker Rob Shapland of Cyonic Cyber. Photograph: Andrew Brookes/Getty Images/Image Source

    The next step is to change the passwords on any important sites and apps – such as banking, investments, pensions and PayPal – says Shapland. Turn on multifactor authentication to bolster security.

    Undo any changes to anti-virus software made by the software on the stick. Then run a virus scan, available for free online, on your laptop.

    If you have been defrauded, it is likely that the damage was done when the stick was first plugged in, says Shapland.

    In the UK, contact Action Fraud, the national fraud reporting centre, and report what happened to your bank.

    Amazon said people had been convicted in connection with the sale of modded devices and the company would continue to work with the authorities to stop the sales. “Piracy is illegal, and customers should not buy these devices,” said the company.

    Continue Reading

  • Evaluating Valuation After Strong Q3 Results and Upbeat AI-Driven Guidance

    Evaluating Valuation After Strong Q3 Results and Upbeat AI-Driven Guidance

    Veeva Systems (VEEV) delivered strong third-quarter results, beating revenue and earnings estimates while sharing an upbeat outlook for the rest of the fiscal year. The company is highlighting continued strength in its core software operations and growing adoption of Veeva AI.

    See our latest analysis for Veeva Systems.

    Despite impressive third-quarter results and upbeat new guidance, Veeva Systems’ share price took a sharp hit, falling nearly 10% in a single day, as investor jitters about future growth tempered enthusiasm. Even after this pullback, Veeva still boasts a 12.7% total shareholder return over the past year and remains solidly in positive territory for 2025. However, recent momentum has faded and the five-year total return lags the broader market.

    If you’re interested in how other healthcare technology innovators are delivering growth and navigating changing markets, check out See the full list for free.

    Given the mixed reaction to Veeva’s earnings beat and guidance hike, the central question for investors is clear: does the recent pullback signal an undervalued opportunity, or is the market fully pricing in Veeva’s growth trajectory from this point forward?

    With the narrative’s fair value estimate of $320.62 sitting well above Veeva’s recent closing price of $244.06, there is a notable gap between the broader analyst consensus and where the market stands today. This invites a closer look at the high-conviction logic propelling this valuation.

    The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers. This enables Veeva to fully integrate industry-leading datasets into its Commercial Cloud, which should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years.

    Read the complete narrative.

    Want to see what’s fueling this bullish narrative? There’s a bold blend of margin expansion, faster revenue growth, and a projected profit trajectory rarely seen in healthcare SaaS. Curious which assumptions are powering that premium? The full narrative spells out the aggressive financial blueprint behind this value call.

    Result: Fair Value of $320.62 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent competitive pressures or slower than expected adoption of Veeva’s new AI products could quickly challenge this optimistic view.

    Find out about the key risks to this Veeva Systems narrative.

    Switching to a price-to-earnings lens, Veeva trades at 46.6x earnings, above both its fair ratio of 32.3x and the broader global healthcare services average of 34.1x. This suggests investors are paying a premium for growth today, which adds valuation risk if expectations reset. Will sentiment hold up if momentum slows?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:VEEV PE Ratio as at Nov 2025

    Prefer to draw your own conclusions from the numbers? You can analyze the facts and put together a personalized investment narrative in just minutes. Do it your way

    A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Veeva Systems.

    Don’t let standout opportunities pass you by. Use the Simply Wall Street Screener to tap into some of the most compelling trends and strategies on the market right now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include VEEV.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • SharpLink Gaming (SBET) Is Down 12.6% After Surging to Profit and Revenue Growth in Q3 – What’s Changed

    SharpLink Gaming (SBET) Is Down 12.6% After Surging to Profit and Revenue Growth in Q3 – What’s Changed

    • SharpLink Gaming reported third quarter 2025 earnings showing revenue and sales of US$10.84 million, up dramatically from US$881,690 a year earlier, and shifted from a net loss to net income of US$104.27 million.

    • This marks a very large increase in both revenue and profit for the company over the prior year quarter.

    • We’ll examine how SharpLink Gaming’s exceptional turnaround in quarterly profitability shapes its current investment narrative.

    Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

    For those considering SharpLink Gaming, the latest earnings release marks a significant moment. The company delivered a striking turnaround, swinging to a US$104.27 million net income following a string of losses and posting quarterly revenue that outpaces recent annual totals. This earnings shock could reshape earlier narratives that focused on persistent unprofitability, heavy past dilution from fundraising, and the untested nature of its quickly rotating leadership team. Positive short-term catalysts may now include greater investor confidence, improved financing options, or momentum behind its blockchain initiatives. However, big risks persist: the scale and source of the sudden profit may raise questions, particularly given last quarter’s multi-million dollar loss, and the history of share issuance may remain a concern. Whether this surge signals lasting change or just a one-off remains to be seen, but it has undoubtedly shaken up the story for both bulls and bears.

    But risks linked to recent dilution and share offerings could still linger after the profit headline. Despite retreating, SharpLink Gaming’s shares might still be trading 32% above their fair value. Discover the potential downside here.

    SBET Community Fair Values as at Nov 2025

    Nineteen fair value estimates from the Simply Wall St Community highlight values ranging from just US$0.02 to a very large US$60,161.54. With opinions diverging this widely, consider both SharpLink’s impressive quarterly profit and the potential risks around past dilution before reaching any conclusions on its future.

    Explore 19 other fair value estimates on SharpLink Gaming – why the stock might be worth less than half the current price!

    Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    Our daily scans reveal stocks with breakout potential. Don’t miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include SBET.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading